



Image Plus Consultants Limited

Unaudited Interim Financial Statements Second Quarter ended August 31, 2024



Contents


	Page
Financial Statements	
Unaudited statement of financial position	3
Unaudited statement of profit or loss and other comprehensive income	4
Unaudited statement of changes in equity	5
Unaudited statement of cash flows	6
Notes to the interim financial statements	7-8
Top 10 Shareholders, Shareholdings of Directors and Senior Officers	9



Directors' Report

The Board of Directors of Image Plus Consultants Limited (the Company) presents the Company's unaudited financial statements for the second quarter ended August 31, 2024.

The financial highlights are as follows:



Revenues & Expenses

Revenues for the second quarter, declined by 3.4% to \$245.3M when compared to the second quarter in the prior year. Revenues for the six months to August 2024 was \$539M representing a decline of \$15M or 2.8% when compared to the similar period in 2023. Revenue performance was impacted by the following factors:

- 1. *Scan volume* for the six-month period to August 31, 2024, was 26,955 cases when compared to 28,729 cases for the same period in the prior year, representing a decline of 6%. This decline was seen across all modalities. Mammography and MRI were launched in August 2023 and February 2024, respectively. The Molynes and 129Pro scan numbers exceeded prior year performance but the volumes at Ocho Rios and Winchester were below prior year performance by 1% and 15% respectively.
- 2. Reduction in the CT modality case count (which accounts for a higher per patient revenue compared to other modalities), due to machine downtime at both the Ocho Rios and Winchester branches. Both units needed CT tube replacements, which are routine and triggered by high volumes. In both cases, the replacement part required was quickly identified, but the repair of the units was impacted by the protracted delivery timelines from the overseas manufacturer. Unfortunately, in August the tube received for the Winchester unit was found to be defective on arrival and had to be replaced under warranty, leading to additional downtime. CT tubes are not easily procured ahead of the need. This is due to its delicate storage condition requirements and the necessity for the local supplier to validate replacements with the manufacturer.



- 3. The 129Pro CT unit malfunctioned again in Q2 and given the findings and monies already invested in that unit in FY2024, the decision was made to retire the unit. To compensate for this, patients were redirected to the Winchester location, which also extended its opening hours. As a result, the entire 129Pro branch operations were consolidated at Winchester to ensure greater efficiency and that branch transitioned to opening seven days per week instead of six to accommodate demand.
- 4. Though growing, our *MRI* and *Mammography scan count performed below expectations*. There continues to be strong demand for MRI and we continue to work on optimizing scan volumes and mix to ensure projected revenues are realised from our investments. For Mammography we are exploring strategies to increase scan volumes, especially in in the competitive Kingston and St. Andrew market.

Looking ahead, we anticipate improved revenue performance for the second half of the year.

Direct costs for both the second quarter and YTD ended 31August 2024 were contained and below prior year by 6.7% or \$6M and 5.5% or \$11M respectively. As a result, the gross profit margin improved to 65% vs 63.8% for the prior year quarter and 64.9% YTD versus 63.8% YTD FY 2024. Conversely, the administrative expense margin for the six months to August 2024 stood at 49.7% vs 41.8% over the prior period. The growth in administrative expenses was due largely to:

- 80% increase in depreciation due to acquisition of imaging equipment and increase in right-of-use asset associated with leases for our locations
- 14.5% or \$20.9M increase in salaries and related expenses resulting from increased staff count
- 52.3% or \$8.1M increase in utilities (driven largely by the MRI unit in Ocho Rios)

Though these expenses were largely planned and in keeping with continued business growth, the revenue shortfall severely impacted our performance.

The aforementioned factors resulted in the Company recording a Net Loss of J\$16.2M for Q2 FY2024 and a Net Profit of J\$15.4M for the six-months to August. This represents a reduction of \$54.9M and J\$87.4M respectively over the prior years.

Balance Sheet

At the end of the first six months of FY2025, total assets stood at J\$1.5B when compared to J\$1.6B at the start of the year. This reduction was primarily due to:

- 1. A \$19M decrease in Property, plant and equipment (PP&E) due to increased depreciation
- 2. A reduction in other investments,
- 3. A structured sale of some of our receivables, effectively reducing our Trade and other receivables

Right-of-Use Asset increased by 39.2% or \$11.2M associated with the lease of our Winchester Road location. Total Liabilities decreased by \$56.4M during the six months to August 2024 due to reduction in trade and other payables. An increase of \$33M was however registered in borrowings as the balance of the MRI unit loan facility was disbursed post end of FY 2024. There was also an increase of \$4.3M in our overdraft facility.



Total equity for the six months to August 2024 declined by \$21.8M to J\$1.1B. This is due to the decrease in our retained earnings as a result of the performance year to date.

Outlook for Remainder of Financial Year 2025

Despite the desired build-out of modalities, we have not achieved the targeted growth in revenue from our diversified revenue streams. We continue to take a very clinical approach to review actions needed to achieve the desired mix of scans by modality and source (private versus public patients). We are also actively scanning the market for inorganic growth opportunities that would add value to our performance.

Discussions with potential partners in regard to the build out of our 33LMR facility are progressing as we work towards the best option for the execution of that project.

The Board of Directors uses this opportunity to acknowledge our committed team members and to express our heartfelt gratitude to the referring physicians who continue to trust us with the imaging needs of their patients.

To our shareholders, we express appreciation for their trust and confidence as we work through our current short-term challenges to deliver the performance to which they have become accustomed and grow the long-term profitability of the Company.

October 14, 2024

Image Plus Consultants Limited Unaudited statement of financial position

August 31, 2024

	Unaudited August 31, 2024 \$	Unaudited August 31, 2023 \$	Audited February 29, 2024 \$
Assets			
Non-current assets			
Property, plant and equipment	1,194,632,991	414,992,637	1,213,261,657
Right of-use asset	39,715,941	34,644,821	28,530,235
Other investments	13,534,449	18,463,526	19,544,971
Deferred tax asset	5,822,008	7,175,308	5,822,008
	1,253,705,389	475,276,292	1,267,158,871
Current assets			
Due from related party	24,611,599	21,978,869	23,321,220
Trade and other receivables	251,872,299	630,808,045	316,747,583
Cash and cash equivalents	515,256	110,237,678	1,659,659
	276,999,154	763,024,592	341,728,462
Total assets	1,530,704,543	1,238,300,884	1,608,887,333
Equitor			
Equity Share capital	465,765,789	465,765,789	465,765,789
Fair value reserve	4,334,664	4,334,664	4,334,664
Retained earnings	583,693,632	496,319,835	605,476,045
Total equity	1,053,794,085	966,420,288	1,075,576,498
Liabilities Non-current liabilities Borrowings	265,616,720	130,421,190	232,568,527
Lease liability	30,471,505	24,795,671	19,138,948
	296,088,225	155,216,861	251,707,475
Current liabilities			
Bank overdraft	12,716,205	-	8,405,872
Trade and other payables	95,378,303	69,423,548	151,135,396
Current portion of borrowings	60,990,660	26,274,748	58,361,564
Current portion of lease liability	11,737,065	11,155,643	11,405,184
Directors' loan	-	-	31,874,422
Income tax payable	-	9,809,796	20,420,922
Total current liabilities	180,822,233	116,663,735	281,603,360
Total liabilities	476,910,458	271,880,596	533,310,835
Total equity and liabilities	1,530,704,543	1,238,300,884	1,608,887,333

The notes on the accompanying pages form an integral part of these financial statements.

Approved for issue by the Directors on 14th October 2024, and signed on its behalf by:

Dr. Karlene McDonnough

Chairman

Dr. Jacqueline Leckie

Image Plus Consultants Limited Unaudited statement of profit or loss and **other comprehensive income** Second quarter ended August 31, 2024

	Unaudited Three months ended August 31, 2024 \$	Unaudited Three months ended August 31, 2023 \$	Unaudited Six months ended August 31, 2024 \$	Unaudited Six months ended August 31, 2023 \$
Revenue	245,346,842	253,960,907	538,805,785	554,144,786
Direct costs Gross profit	(85,902,298) 159,444,544	(92,041,185) 161,919,722	(189,357,519) 349,448,266	(200,447,009) 353,697,777
Administrative expenses Net movement on impairment provision Depreciation and amortisation Other expense Operating (loss)/profit	(142,558,962) - (27,080,720) (10,195,138)	(114,242,646) - (15,492,072) (135,437) 32,049,567	(267,941,628) - (53,746,647) - 27,759,991	(231,649,996) - (29,900,997) (181,401) 91,965,383
Other income Foreign exchange gain Finance income Interest expense (Loss)/profit before tax	436,996 263,151 571,352 (7,328,430) (16,252,069)	3,000 1,835,620 7,750,352 (2,981,405) 38,657,134	436,996 338,656 1,137,857 (14,272,423) 15,401,077	15,500 2,863,235 12,625,465 (4,698,357) 102,771,226
(Loss)/profit for the period/year being total comprehensive income (loss) for the period/year	(16,252,069)	38,657,134	15,401,077	102,771,226
Earnings per share	(0.01)	0.03	0.01	0.08

The notes on the accompanying pages form an integral part of these financial statements.

Image Plus Consultants Limited Unaudited statement of changes in equity Second quarter ended August 31, 2024

	Share capital \$	Fair value reserve \$	Accumulated surplus \$	Total \$
Balance at February 28, 2023 - Audited	465,765,789	4,334,664	467,915,590	938,016,043
Transaction with owners				
Dividend for the year	-	-	(74,366,981)	(74,366,981)
Profit for the six months ended August 31, 2023 Balance at August 31, 2023 – Unaudited	465,785,789	4,334,664	102,771,226 496,319,835	102,771,226 966,420,288
Balance at February 29, 2024 - Audited	465,765,789	4,334,664	605,476,045	1,075,576,498
Dividend for the year	-	-	(37,183,490)	(37,183,490)
Profit for the six months being total comprehensive income	-	-	15,401,077	15,401,077
Balance at August 31, 2024 – Unaudited	465,765,789	4,334,664	583,693,632	1,053,794,085

The notes on the accompanying pages form an integral part of these financial statements.

Image Plus Consultants Limited Unaudited statement of cash flows Second quarter ended August 31, 2024

	Unaudited Six months ended August 31, 2024 \$	Unaudited Six months ended August 31, 2023 \$	Audited Year ended February 29, 2024 \$
Cash flows from operating activities: Profit before tax	15,401,077	102,771,226	211,927,436
Adjustments for: Interest expense Interest expense on lease liabilities Interest income Income tax expense Depreciation Amortisation on right of use asset	12,487,485 1,784,938 (1,137,857) - 41,530,850 12,215,797 82,282,290	3,398,137 1,300,220 (12,625,465) - 23,886,030 6,014,967 124,745,115	11,695,932 2,465,968 (84,500) 12,398,433 51,985,372 12,129,553 302,518,194
Decrease(increase) in receivables Increase in due from related parties (Decrease)/increase in payables and accruals Decrease in directors' loan	64,875,284 (1,290,379) (55,757,093) (31,874,422)	(332,390,583) (2,323,253) 3,354,984	(18,330,121) (3,665,604) 85,066,832
Cash generated from/(used in) operations	58,235,680	(206,613,737)	365,589,301
Income tax paid Interest paid	(20,420,922) (12,487,485) 25,347,273	(30,852,052) (3,398,137) (240,863,926)	(32,639,359) (11,091,510) 321,858,432
Net cash provided by/(used in) operations	20,047,270	(240,000,020)	021,000,402
Cash flow from investing activities Interest received Purchase of property, plant and equipment Decrease in investment Decrease in other investment Net cash (used in)/provided by investing activities	1,137,857 (22,902,184) - 6,010,522 (15,753,805)	12,625,465 (120,111,189) 435,189,405 - 327,703,681	84,500 (946,479,551) 435,016,560 444,700 (510,933,791)
Cash flow from financing activities			
Repayment of borrowings Repayment of lease liability Interest paid on lease payments Proceeds from borrowings Dividend Net cash (used in)/provided by financing activities	(32,359,711) (11,737,065) (1,784,938) 68,037,000 (37,183,490) (15,028,204)	(11,370,000) (5,130,470) (1,300,220) 58,105,600 (74,366,981) (34,062,071)	(29,641,032) (10,537,652) (2,465,968) 241,880,785 (74,366,981) 124,869,152
Net (decrease)/increase in cash and cash equivalents Cash and cash equivalents at beginning of period/year Cash and cash equivalents at end of period/year	(5,454,736) (6,746,213) (12,200,949)	52,777,684 57,459,994 110,237,678	(64,206,207) 57,459,994 (6,746,213)

The notes on the accompanying pages form an integral part of these financial statements.

Image Plus Consultants Limited Notes to the unaudited interim financial statements

Second quarter ended August 31, 2024

1. General information and nature of operations

Image Plus Consultants Limited was incorporated under the laws of Jamaica on February 27, 1996 and is domiciled in Jamaica. The company operates from 3 locations in Kingston – 2A Molynes Road, 3A Winchester Road, 129 Old Hope Road (Liguanea) and White River North Commercial Complex, Shops 8-10, in Ocho Rios, St. Ann.

The company offers diagnostic X-Ray, Ultrasound, Computerized Tomography, Nuclear medicine, Fluoroscopy, Interventional Radiology Magnetic Resonance Imaging (MRI) and Mammography services under the business name of Apex Radiology.

The company was listed on the Jamaica Stock Exchange (JSE) Junior Market via Initial Offering (IPO) on January 20, 2023.

2. Statement of compliance

a Basis of preparation

These financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) IAS 34, Interim Financial Reporting.

The interim financial report is to be read in conjunction with the audited financial statements for the year ended February 28, 2024. The material accounting policies adopted are consistent with those of the audited financial statements for the year ended February 28, 2024.

b Critical judgements and sources of estimation uncertainty

The preparation of these financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements. These estimates are based on historical experience and management's best knowledge of current events and actions. Actual results may differ from these estimates and assumptions.

3. Cash and cash equivalents

	Unaudited six months ended August 31, 2024 \$	Unaudited six months ended August 31, 2023 \$	Audited year ended February 29, 2024 \$
Bank and cash	515,256	110,237,678	1,659,659
Bank overdraft	(12,716,205)	-	(8,405,872)
Cash and cash equivalents	(12,200,949)	110,237,678	(6,746,213)

Image Plus Consultants Limited Notes to the unaudited interim financial statements

Second quarter ended August 31, 2024

Basic and diluted earnings per share

	Unaudited Six months ended August 31, 2024 \$	Unaudited Six months ended August 31, 2023 \$
Authorised ordinary units of no par value	Unlimited	Unlimited
Issued ordinary units of no par value	1,239,449,680	1,239,449,680
Stated capital: Issued and fully paid ordinary stocks of no par value	465,765,789	465,765,789
Earnings per share	Unaudited Six months ended August 31, 2024 \$	Unaudited Six months ended August 31, 2023
Profit attributable to shareholders	15,401,077	102,771,220
Weighted average number of shares	1,239,449,680	1,239,449,680
Basic and diluted earnings per share	0.01	0.0
	Unaudited three months ended August 31, 2024 \$	Unaudited three months ended August 31, 2023 \$
Profit attributable to shareholders	(16,252,108)	38,657,134

0.03

(0.01)

Image Plus Consultants Limited

List of Top Ten Shareholders As at August 31, 2024

Names	Shares Held	Percentages %
Dr. Karlene McDonnough	303,417,282	24.48
Dr. Lilieth Bridgewater	158,091,321	12.75
Dr. Marian Allison Vaughan	99,155,974	8.00
Mrs. Kisha Anderson	2,750,000	0.22
Mr. Karl Townsend	2,587,400	0.21
Ms. Carolyn DaCosta	614,561	0.05
Dr. Jacqueline Leckie	50,000	0.00
Dr. Gordon Bradshaw	Connected	-
Dr. Steven Lewis	Connected	-
	566,666,538	45.71

Connected parties	Connected to		
Quad G Limited	Dr.Gordon Bradshaw	209,763,421	16.92
SureScan Radiology Service Limited	Dr.Steven Lewis	50,577,987	4.08
Craig DaCosta	Ms. Carolyn DaCosta	28.922	0.00
Vyacheslav Moskalev	Dr. Karlene McDonnough	786,200	0.06
Katherine Pottinger	Dr. Karlene McDonnough	200,000	0.02
Kimberly Lyon	Dr. Karlene McDonnough	500,000	0.04
Karen Gauntlett	Dr. Karlene McDonnough	500,000	0.04
Kai Bridgewater	Dr. Lilieth Bridgewater	2,000,000	0.16
Kiri – Ann Bridgewater	Dr. Lilieth Bridgewater	4,522,623	0.36
Taryn Bridgewater	Dr. Lilieth Bridgewater	1,000,000	0.08
Lee – Ann Bridgewater Elizabeth Thompson/	Dr. Lilieth Bridgewater	2,000,000	0.16
Rebekah Hoilet Duncan	Mrs.Kisha Anderson	1,000,000	0.08
Janice Mcleod	Mr. Karl Townsend	24,275	0.00
Courtney – Ann Vaughan	Dr. Marian Allison Vaughan	250,000	0.02
Mathieu Vaughan	Dr. Marian Allison Vaughan	250,000	0.02
Combined Connected Parties Holdings	<u> </u>	273,403,428	22.06
Combined Holdings		840,069,966	67.77


Senior Managers Shareholder

Names	Shares Held	Percentages %
	0.750.000	0.00
Kisha Anderson	2,750,000	0.22
Althia Frew Jones	600,000	0.05
Ramona Green	545,608	0.04
Kerry McDonnough Davis	525,000	0.04
Anthony Grizzle	278,198	0.02
Marcia Dolphy	200,000	0.02
Nicola Beccan-Morgan	100,000	0.01
, and the second	4,998,806	0.40

Image Plus Consultants Limited List of Top Ten Shareholders As at August 31, 2024

Shareholders

	Shares Held	Percentages %
1. Dr.Karlene McDonnough	303,417,282	24.48
Quad G Limited	209.763.421	16.92
Dr.Lilieth Bridgewater	158,091,321	12.96
4. Advanced Imaging Limited	113,565,156	9.16
5. Dr.Marian Allison Vaughan	99,155,974	8.00
6. Barita Investments Ltd	58,680,147	4.73
7. SureScan Radiology Services Limited	50,577,987	4.08
8. Jamaica Money Market Brokers Ltd	11,850,000	0.96
9. Solid Life & General Insurance Brokers Limited	10,290,000	0.81
10.NCB Capital Market	9,600,000	0.77
Total	1,024,991,288	82.69
Total Issued Capital	1,239,449,680	



4 CONVENIENT oca

KINGSTON BRANCHES:

- ► MOLYNES 2A MOLYNES ROAD
 - · Ultrasounds · X-Rays · Mammograms
- ► WINCHESTER 3A WINCHESTER ROAD
 - · CT Scans · Ultrasounds · X-Rays
 - · Fluoroscopy · Nuclear Medicine
 - · Interventional Studies
- ▶ 129 PRO 129 OLD HOPE ROAD
 - · CT Scans · Ultrasounds · X-Rays

OCHO RIOS BRANCH:

- ► OCHO RIOS WHITE RIVER NORTH **COMMERCIAL COMPLEX**
 - · MRI · Mammograms · CT Scans
 - · Ultrasounds · X-Rays

